NCT03083834

Brief Summary

In mitotane treated patients, serum cortisol cannot be used to diagnose hypoadrenalism, since mitotane increases cortisol binding globulin levels (CBG), artificially raising total cortisol. Salivary free cortisol (SC) is not affected by CBG alterations, and reflects the free serum cortisol. In the current study, investigators will assess serum and SC responses during low-dose cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on steroid replacement therapy and in patients who suffer from hypoadrenlism caused from other etiology. Investigators will compare results between groups and try to demonstrate the superiority of SC in assessing adrenal function in mitotane treated patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 14, 2017

Completed
Same day until next milestone

Study Start

First participant enrolled

March 14, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 20, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

January 18, 2019

Status Verified

January 1, 2019

Enrollment Period

2.8 years

First QC Date

March 14, 2017

Last Update Submit

January 17, 2019

Conditions

Keywords

cosyntropinsalivary free cortisolmitotane

Outcome Measures

Primary Outcomes (1)

  • Salivary free cortisol

    Salivary free cortisol concentrations during intravenous low dose cosyntropin stimulation test..

    1 day

Secondary Outcomes (1)

  • serum cortisol

    1 day

Study Arms (3)

healthy subjects

EXPERIMENTAL

low-dose cosyntropin stimulation test

Diagnostic Test: Cosyntropin stimulation test

hypoadrenal mitotane treated patients

EXPERIMENTAL

low-dose cosyntropin stimulation test

Diagnostic Test: Cosyntropin stimulation test

hypoadrenal no-mitotane treated patients

EXPERIMENTAL

low-dose cosyntropin stimulation test

Diagnostic Test: Cosyntropin stimulation test

Interventions

At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.

healthy subjectshypoadrenal mitotane treated patientshypoadrenal no-mitotane treated patients

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • mitotane treated
  • known hypoadrenlism

You may not qualify if:

  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bnai Zion MC

Haifa, Israel

RECRUITING

MeSH Terms

Conditions

Adrenal InsufficiencyAdrenal Gland Neoplasms

Condition Hierarchy (Ancestors)

Adrenal Gland DiseasesEndocrine System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasms

Study Officials

  • Leonard Saiegh, MD

    Bnai Zion Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Leonard Saiegh, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 14, 2017

First Posted

March 20, 2017

Study Start

March 14, 2017

Primary Completion

December 31, 2019

Study Completion

December 31, 2019

Last Updated

January 18, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations